BG
BCYC

Bellevue Group’s Bicycle Therapeutics BCYC Stock Holding History

Bellevue Group’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,000
Closed -$324K – 167
2024
Q2 		$324K Buy
16,000
+3,500
+28% +$79.1K 0.01% 138
2024
Q1 		$311K Sell
12,500
-7,500
-38% -$159K ﹤0.01% 145
2023
Q4 		$362K Sell
20,000
-19,200
-49% -$318K 0.01% 142
2023
Q3 		$788K Buy
39,200
+14,200
+57% +$325K 0.01% 137
2023
Q2 		$638K Sell
25,000
-28,200
-53% -$655K 0.01% 139
2023
Q1 		$1.13M Sell
53,200
-17,000
-24% -$426K 0.02% 126
2022
Q4 		$2.08M Sell
70,200
-27,900
-28% -$748K 0.03% 124
2022
Q3 		$2.28M Buy
98,100
+13,700
+16% +$326K 0.03% 120
2022
Q2 		$1.42M Buy
84,400
+47,900
+131% +$1.01M 0.02% 134
2022
Q1 		$1.6M Sell
36,500
-17,200
-32% -$803K 0.02% 140
2021
Q4 		$3.27M Sell
53,700
-12,000
-18% -$662K 0.03% 135
2021
Q3 		$2.73M Buy
+65,700
New +$2.3M 0.03% 142

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Bellevue Group's BCYC Position: Q3 2024 in Review

Bellevue Group sold out of Bicycle Therapeutics (BCYC) in Q3 2024, closing a stake of 16,000 shares — an estimated $324K sold.

Bellevue Group first reported a position in BCYC in Q3 2021 and held it in 12 quarters. The position peaked at $3.27M in Q4 2021. 105 funds tracked by Wall St. Rank hold BCYC as of Q3 2024.

  • Bellevue Group reported no remaining Bicycle Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bellevue Group sold 16,000 Bicycle Therapeutics shares in Q3 2024, an estimated $324K.
  • Bellevue Group first reported a position in Bicycle Therapeutics in Q3 2021 and held it in 12 quarters.
  • Bellevue Group's Bicycle Therapeutics position peaked at $3.27M in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2024.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.